Operating Profit Margin
since 2005
Calculation
Cytokinetics Inc., operating profit margin, long-term trends, calculation
| Operating profit margin | = | 100 | × | Operating income (loss)1 | ÷ | Revenues1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2022 | -342.75% | = | 100 | × | (324,202) | ÷ | 94,588) |
| Dec 31, 2021 | -264.54% | = | 100 | × | (186,313) | ÷ | 70,428) |
| Dec 31, 2020 | -168.27% | = | 100 | × | (93,943) | ÷ | 55,828) |
| Dec 31, 2019 | -367.97% | = | 100 | × | (98,867) | ÷ | 26,868) |
| Dec 31, 2018 | -282.26% | = | 100 | × | (88,916) | ÷ | 31,501) |
| Dec 31, 2017 | -848.26% | = | 100 | × | (113,396) | ÷ | 13,368) |
| Dec 31, 2016 | 17.56% | = | 100 | × | 18,687) | ÷ | 106,407) |
| Dec 31, 2015 | -130.53% | = | 100 | × | (37,407) | ÷ | 28,658) |
| Dec 31, 2014 | -31.43% | = | 100 | × | (14,754) | ÷ | 46,940) |
| Dec 31, 2013 | -110.59% | = | 100 | × | (33,894) | ÷ | 30,648) |
| Dec 31, 2012 | -535.22% | = | 100 | × | (40,457) | ÷ | 7,559) |
| Dec 31, 2011 | -1,199.10% | = | 100 | × | (47,964) | ÷ | 4,000) |
| Dec 31, 2010 | -1,926.08% | = | 100 | × | (49,635) | ÷ | 2,577) |
| Dec 31, 2009 | 32.00% | = | 100 | × | 26,095) | ÷ | 81,538) |
| Dec 31, 2008 | -475.68% | = | 100 | × | (59,079) | ÷ | 12,420) |
| Dec 31, 2007 | -414.67% | = | 100 | × | (56,487) | ÷ | 13,622) |
| Dec 31, 2006 | -1,961.56% | = | 100 | × | (61,338) | ÷ | 3,127) |
| Dec 31, 2005 | -500.82% | = | 100 | × | (44,633) | ÷ | 8,912) |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in thousands
- Operating Income (Loss) Trend
- The operating income exhibits considerable volatility during the analyzed period, with fluctuations between significant losses and brief positive results. Initial years show sustained negative operating income from 2005 through 2008, with the lowest recorded value in 2006 at -61,338 thousand US dollars. A notable positive spike occurred in 2009, where operating income reversed to a profit of 26,095 thousand US dollars. Subsequently, the company returned to persistent negative operating income from 2010 onwards, reaching increasingly severe losses in recent years with the deepest deficit in 2022 at -324,202 thousand US dollars.
- Revenue Patterns
- Revenues demonstrate a generally upward trend, albeit with significant volatility and some years of decline. Revenue increased substantially between 2008 and 2009, peaking at 81,538 thousand US dollars in 2009. However, this was followed by a sharp decline in 2010 to 2,577 thousand US dollars. Afterward, revenues experienced growth with intermittent fluctuations, reaching a peak in 2016 at 106,407 thousand US dollars. Revenue dipped again in 2017 and 2019 but showed resurgence in 2021 and 2022, culminating in the highest revenue of the period at 94,588 thousand US dollars in 2022.
- Operating Profit Margin Dynamics
- Operating profit margin percentages are consistently negative for the majority of the periods, indicating operational inefficiency relative to revenues. Extreme negative margins occur particularly in years with high operating losses and relatively low revenues, such as in 2006 (-1961.56%) and 2007 (-414.67%). The margin turned positive briefly in 2009 (32%) and 2016 (17.56%), coinciding with operating income profit years. However, these positive margins were not sustained, with severe negative margins resuming thereafter, reaching a low of approximately -848.26% in 2017 and worsening further in 2022 to around -342.75%. This pattern suggests persistent challenges in converting revenues into operating profits over the decade-plus span.
- Summary Insight
- The financial data reveals a company with ongoing operating losses despite revenue growth in certain years. The sporadic profitability in operating income and positive margins are isolated events within a broader context of substantial negative results. The growth in revenue does not correspond with proportional improvements in operating profitability, indicating structural or operational issues impacting cost management or pricing efficiency. The increasing magnitude of operating losses in the latter years necessitates focused analysis into cost drivers and revenue quality to address sustainability concerns.
Comparison to Competitors
Cytokinetics Inc., operating profit margin, long-term trends, comparison to competitors
| Cytokinetics Inc. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|
| Dec 31, 2022 | -342.75% | 31.21% | 38.57% | 27.61% | 27.17% | 38.93% | 18.69% | 48.23% |
| Dec 31, 2021 | -264.54% | 31.89% | 31.44% | 25.35% | 36.72% | 55.67% | 25.57% | 36.73% |
| Dec 31, 2020 | -168.27% | 24.81% | 37.70% | 18.99% | 16.72% | 42.09% | 24.19% | 46.03% |
| Dec 31, 2019 | -367.97% | 39.03% | 43.57% | 18.25% | 19.38% | 28.10% | 17.99% | 28.77% |
| Dec 31, 2018 | -282.26% | 19.49% | 45.55% | 17.11% | 37.83% | 37.77% | 15.53% | 20.84% |
| Dec 31, 2017 | -848.26% | 33.99% | 45.76% | 16.48% | 55.04% | 35.41% | 14.19% | 4.95% |
| Dec 31, 2016 | 17.56% | 36.60% | 44.74% | 16.29% | 58.87% | 27.38% | 13.40% | 0.58% |
| Dec 31, 2015 | -130.53% | 32.97% | 40.44% | 16.87% | 69.03% | 30.51% | 13.77% | -45.23% |
| Dec 31, 2014 | -31.43% | 17.09% | 32.03% | 17.23% | 62.37% | 29.74% | 14.82% | -119.30% |
| Dec 31, 2013 | -110.59% | 30.14% | 32.25% | 17.13% | 41.87% | 36.11% | 12.30% | -74.54% |
| Dec 31, 2012 | -535.22% | 31.65% | 33.52% | 17.33% | 42.67% | 33.20% | 11.85% | 0.15% |
| Dec 31, 2011 | -1,199.10% | — | 28.19% | 16.27% | 46.77% | -46.02% | 10.62% | 8.07% |
| Dec 31, 2010 | -1,926.08% | — | 37.82% | 16.41% | 53.62% | -21.23% | 11.72% | -485.51% |
| Dec 31, 2009 | 32.00% | — | 38.37% | 13.79% | 54.55% | -19.54% | 10.38% | -602.63% |
| Dec 31, 2008 | -475.68% | — | 35.50% | 14.72% | 52.68% | -37.67% | 11.71% | -263.65% |
| Dec 31, 2007 | -414.67% | — | 27.81% | 15.79% | 57.98% | -91.55% | 10.00% | -210.94% |
| Dec 31, 2006 | -1,961.56% | — | 27.71% | 15.82% | -29.32% | -169.68% | 6.38% | -105.86% |
| Dec 31, 2005 | -500.82% | — | 40.33% | 15.84% | 61.41% | -187.97% | 10.01% | -93.15% |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).